Genome-wide CRISPR screens map synthetic lethal interactions across recurrent cancer driver alterations.
- Open access
Genome-wide CRISPR screens identify 15 cancer driver alterations with numerous synthetic lethal interactions, revealing new therapeutic targets.
- Why it matters: Targeting cancer driver gene alterations, especially those that are not easily druggable like tumor suppressors, remains a significant challenge in cancer therapy. Understanding synthetic lethality can open new avenues for treatment.
- What they did: Researchers performed genome-wide CRISPR screens on isogenic cell lines and analyzed data from the DepMap to map SL interactions across 15 driver alterations, validating several key interactions.
- The result: The study provides a comprehensive resource of genetic interactions that can inform the discovery of novel drug targets and biological insights, advancing precision cancer therapy.